Adjuvant Chemotherapy and the Role of Chemotherapy Resistance Testing for Stage I Non-Small Cell Lung Cancer

Thoracic Surgery Clinics

Volumn 17, Issue 2, 2007, Pages 287-299

  d'Amato, Thomas A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; VINCA ALKALOID;

ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; HUMAN; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 34249854350     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2007.03.015     Document Type: Review

References (29)

1. American Cancer Society. Cancer facts and figures 2006 (2006), American Cancer Society, Atlanta p. 13-5
2. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7.
3. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
4. Strauss G.M., Herndon J., Maddaus M.A., et al. Randomized clinical one page of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of cancer and leukemia Group B (CALGB) protocol 9633. J Clin Oncol 22 (2004) 7019 [ASCO Annual Meeting Proceedings, New Orleans, Louisiana, USA]
5. Winton T.L., Livingston R., Johnson D., et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10. N Engl J Med 352 (2005) 2289-2297
6. Douillard J., Rosell R., Delena M., et al. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up on behalf of the Adjuvant Navelbine International Trialist Association. J Clin Oncol 23 (2005) 7013 [ASCO Annual Meeting Proceedings, Orlando, Florida, USA]
7. Strauss G., Herndon J., Maddaus M., et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of cancer and leukemia group B (CALGB) protocol 9633. J Clin Oncol 24 18S (2006) 7007 [ASCO Annual Meeting Proceedings Part I]
8. Schrag D., Garewal H., Burstein H., et al. American Society of Clinical Oncology technology assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22 (2004) 3631-3638
9. Samson D., Seidenfeld J., Ziegler K., et al. Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 22 (2004) 3618-3630
10. Fruehauf J., and Alberts D. In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol 23 (2005) 3641-3643
11. Nagourney R. Chemotherapy sensitivity and resistance assays: a systemic review?. J Clin Oncol 23 (2005) 3640-3641
12. Medicare coverage: MCAC Laboratory and Diagnostic Services Panel Human Tumor Assay Systems. Minutes of November 15-16, 1999, Meeting. Available at: http://www.cms.hhs.gov/mcd/viewmcac.asp?where=basket&mid=14&basket=mcac:14:Human+Tumor+Assay+Systems+%28Laboratory+and+Diagnostic+Services+Panel%29:11/15/1999. Accessed April 23, 2007.
13. Fruehauf J.P., and Bosanquet A.G. In vitro determination of drug response: a discussion of clinical applications. Principles and Practice of Oncology: Updates 7 12 (1993) 1-16
14. Kern D., and Weisenthal L. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 82 (1990) 582-588
15. d'Amato T., Landreneau R., McKenna R., et al. Prevalence of in vitro extreme chemotherapy resistance in resected non-small cell lung cancer. Ann Thorac Surg 81 (2006) 440-446
16. d'Amato T.A., Landreneau R.J., Ricketts W., et al. Chemotherapy resistance and oncogene expression in non-small cell lung cancer. J Thorac Cardiovasc Surg 133 (2007) 352-363
17. Mehta R., Bomstein R., Yu I.R., et al. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res Treat 66 (2001) 225-237
18. Holloway R., Mehta R., Finkler N., et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 87 (2002) 8-16
19. Loizzi V., Chan J., Osann K., et al. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 189 (2003) 1301-1307
20. Parker R.J., Fruehauf J.P., Mehta R., et al. A prospective blinded study of predictive value of extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. J Neurooncol 66 (2004) 365-375
21. Schiller J., Harrington D., Belani C., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
22. Rosell R., Cobo M., Isla D., et al. ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p). J Clin Oncol 23 (2005) 7002 [ASCO Annual Meeting Proceedings, Orlando, Florida, USA]
23. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 (2006) 983-991
24. Nevins J., Petersen R., Mukherjee S., et al. A genomic strategy to refine prognosis in early stage non-small cell lung carcinoma (NSCLC). J Clin Oncol 24 18S (2006) 7026 [ASCO Annual Meeting Proceedings Part I]
25. Potti A., Mukherjee S., Petersen R., et al. A genomic strategy to refine prognosis in early-stage non-small cell lung cancer. N Engl J Med 355 (2006) 570-580
26. d'Amato TA, Fernando HC, Chan BY, et al. Differential gene expression associated with early tumor recurrence and long disease free survival in early stage lung cancer. Presented at the Society of Surgical Oncology 60th Annual Meeting. Washington, DC, March 15-18, 2007.
27. Sun Z., and Yang P. Gene expression profiling on lung cancer outcome prediction: present clinical value and future premise. Cancer Epidemiol Biomarkers Prev 15 (2006) 2063-2068
28. Smith DL, Shahbahrami B, Covic S, et al. Identification of amplifications and deletions in taxol resistant ovarian tumors by competitive genomic hybridization screening. Presented at the 4th International Meeting on Cancer Molecular Markers. Stone Mountain, GA, September 8-10, 2006.
29. Wieand H. Chemotherapy sensitivity and response assays: are the ASCO guidelines for clinical trial design too restrictive?. J Clin Oncol 23 (2005) 3643-3644